10 terminated. 10 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Terminated 10 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery Prothrombin Complex Concentrate, Human, Fresh Frozen Plasma - Valvular Heart Surgery | Phase 4 | Terminated | SHI Jia | 476 | 2023-10-25 | 2026-06-24 |
| An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US), Haemophilia Joint Health Score (HJHS) - Hemophilia A, Hemophilia B | Phase 4 | Terminated | Swedish Orphan Biovitrum | 10 | 2023-08-24 | 2025-01-16 |
| Factor In the Initial Resuscitation of Severe Trauma 2 Patients Fibrinogen + PCC, Frozen Plasma - Traumatic Hemorrhage, Coagulopathy | Phase 4 | Terminated | University Health Network, Toronto | 142 | 2021-04-01 | 2026-10-21 |
| Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures Emicizumab - Hemophilia A | Phase 4 | Terminated | Genentech, Inc. | 14 | 2018-06-28 | 2021-03-01 |
| INdividualized ITI Based on Fviii(ATE) Protection by VWF Wilate - Hemophilia A With Inhibitor, Hemophilia A | Phase 4 | Terminated | University of California, Davis | 1 | 2017-06-01 | 2020-05-29 |
| Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A Optivate 500IU - Haemophilia A | Phase 4 | Terminated | Bio Products Laboratory | 7 | 2014-11-21 | 2021-07-22 |
| Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings moroctocog alfa (AF-CC) (ReFacto AF), Laboratory tests - Hemophilia A | Phase 4 | Terminated | Pfizer | 208 | 2009-05-01 | 2014-09-01 |
| Study Evaluating The Safety Of Xyntha In Usual Care Settings Moroctocog alfa(AF-CC), Blood draw for laboratory testing - Hemophilia A | Phase 4 | Terminated | Pfizer | 12 | 2009-02-01 | 2012-01-20 |
| Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients Alphanate SD/HT - Von Willebrand Disease | Phase 4 | Terminated | Grifols Biologicals, LLC | 4 | 2008-07-08 | 2026-09-30 |
| Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A Kogenate (BAY 14-2222) - Hemophilia A | Phase 4 | Terminated | Bayer | 1 | 2006-05-01 | 2014-12-18 |
Hemophilia A (8) · Hemophilia B (3) · Hemostatic Disorders (3) · Coagulation Protein Disorders (1) · Hematologic Diseases (1) · Wounds and Injuries (1) · von Willebrand Diseases (1)
Blood Coagulation Disorders, Inherited (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Hemic and Lymphatic Diseases (10) · Hemorrhagic Disorders (10) · Coagulation Protein Disorders (9) · Hematologic Diseases (9) · Cardiovascular Diseases (3) · Genetic Diseases, X-Linked (3) · Vascular Diseases (3) · Blood Platelet Disorders (1)
F8 protein, human (2) · BAY 14-2222 (1) · Blood Specimen Collection (1) · Clinical Laboratory Techniques (1) · Factor IX (1) · Factor VIII (1) · Fibrinogen (1) · High-Energy Shock Waves (1) · emicizumab (1) · optivate (1) · prothrombin complex concentrates (1) · recombinant factor VIII SQ (1) · von Willebrand Factor (1)
Pfizer (2) · Bayer (1) · Bio Products Laboratory (1) · Genentech, Inc. (1) · Grifols Biologicals, LLC (1) · SHI Jia (1) · Swedish Orphan Biovitrum (1) · University Health Network, Toronto (1) · University of California, Davis (1)
United States (4) · France (2) · Germany (2) · Hungary (2) · Italy (2) · Romania (2) · Spain (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Bulgaria (1) · Canada (1) · China (1) · Colombia (1) · Croatia (1)
Eric Wolford (1) · Jia Shi, M.D. (1) · Lijian Pei, M.D. (1) · Luis T Da Luz, MD (1) · Sandra Camprubi (1) · Stefan Lethagen, MD, PhD (1)